Research map: Understanding extrapulmonary neuroendocrine carcinomas: Survival, prognosis, and patient quality of life

Back to the article

Papers in this map

  1. The 2019 WHO classification of tumours of the digestive system · Irıs D. Nagtegaal · 2019 · 4271 citations · Cited by this paper
  2. Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues · Charles W Shi · 2026 · Cites this paper
  3. Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors · 2026 · Related
  4. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer · Leora Horn · 2018 · 3642 citations · Cited by this paper
  5. Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors · Akihiro Ohmoto · 2026 · Cites this paper
  6. Glioblastoma and resistance to radiotherapy: role of cancer stem cells subpopulations, hypoxia and therapeutic strategies · 2026 · Related
  7. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal · Guido Rindi · 2018 · 1164 citations · Cited by this paper
  8. Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception · 2026 · Related
  9. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study · Halfdan Sørbye · 2012 · 1039 citations · Cited by this paper
  10. Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation · 2026 · Related
  11. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms · Guido Rindi · 2022 · 1032 citations · Cited by this paper
  12. Multigene assays in early breast cancer: Current evidence, limits and future directions · 2026 · Related
  13. Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy · Staffan Welin · 2011 · 299 citations · Cited by this paper
  14. Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection · 2026 · Related
  15. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases · Arvind N. Dasari · 2017 · 283 citations · Cited by this paper
  16. Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer · 2025 · Related
  17. Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas · Olca Baştürk · 2014 · 261 citations · Cited by this paper
  18. Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study · 2026 · Related
  19. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome · Jules L. Derks · 2017 · 234 citations · Cited by this paper
  20. Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies · 2026 · Related
  21. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer · Charles M. Rudin · 2023 · 182 citations · Cited by this paper
  22. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial · Ying Cheng · 2024 · 162 citations · Cited by this paper
  23. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms · Andreas Venizelos · 2021 · 158 citations · Cited by this paper
  24. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma · Julien Hadoux · 2015 · 141 citations · Cited by this paper
  25. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials · Namrata Vijayvergia · 2020 · 114 citations · Cited by this paper
  26. Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges · Elisa Andrini · 2022 · 79 citations · Cited by this paper
  27. Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas · Ingrid Holst Olsen · 2012 · 75 citations · Cited by this paper
  28. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin · Adele Busico · 2019 · 68 citations · Cited by this paper
  29. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas · Martin Wermke · 2022 · 68 citations · Cited by this paper
  30. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin · Jaume Capdevila · 2023 · 58 citations · Cited by this paper
  31. Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial · Thomas A. Walter · 2023 · 53 citations · Cited by this paper
  32. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward? · Rocio García‐Carbonero · 2023 · 52 citations · Cited by this paper
  33. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms · Jennifer Rachel Eads · 2023 · 51 citations · Cited by this paper
  34. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas · Arvind N. Dasari · 2022 · 49 citations · Cited by this paper
  35. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas · Ángela Lamarca · 2016 · 46 citations · Cited by this paper
  36. HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors · Mary Ellen Molloy · 2024 · 39 citations · Cited by this paper
  37. Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis · Mairead Geraldine McNamara · 2020 · 38 citations · Cited by this paper
  38. Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study · Halfdan Sørbye · 2025 · 36 citations · Cited by this paper
  39. Extrapulmonary poorly differentiated NECs, including molecular and immune aspects · Mairead Geraldine McNamara · 2020 · 35 citations · Cited by this paper

Source: OpenAlex (CC0)